2021
Pioglitazone transiently stimulates paraoxonase-2 expression in male nonhuman primate brain: Implications for sex-specific therapeutics in neurodegenerative disorders
Blackburn JK, Jamwal S, Wang W, Elsworth JD. Pioglitazone transiently stimulates paraoxonase-2 expression in male nonhuman primate brain: Implications for sex-specific therapeutics in neurodegenerative disorders. Neurochemistry International 2021, 152: 105222. PMID: 34767873, PMCID: PMC8712400, DOI: 10.1016/j.neuint.2021.105222.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAryldialkylphosphataseBrainFemaleMitochondriaNeurodegenerative DiseasesNeuroprotective AgentsOxidative StressPioglitazonePrimatesSex FactorsConceptsPON2 expressionParkinson's diseaseParaoxonase 2Male African green monkeysShort-term animal modelsOxidative stressPeroxisome proliferator-activated receptor gammaEffect of pioglitazoneWeeks of treatmentProliferator-activated receptor gammaNonhuman primate brainParaoxonase-2 expressionRegion-dependent expressionSex-specific therapeuticsAnti-diabetic drug pioglitazoneAfrican green monkeysDorsolateral prefrontal cortexOral pioglitazonePreclinical evidenceSubstantia nigraClinical trialsPON2 mRNAAnimal modelsPioglitazonePrimate brainNeuroprotection through G-CSF: recent advances and future viewpoints
Rahi V, Jamwal S, Kumar P. Neuroprotection through G-CSF: recent advances and future viewpoints. Pharmacological Reports 2021, 73: 372-385. PMID: 33389706, DOI: 10.1007/s43440-020-00201-3.Peer-Reviewed Original ResearchConceptsGranulocyte-colony stimulating factorNeutrophilic granulocyte lineageNumerous cell typesJAK/STATG-CSF receptorPI3K/AktInhibition of apoptosisTransduction pathwaysHaemopoietic stem cellsMAP kinaseNeuronal differentiationHematopoietic stemCell typesGranulocyte lineageNeurological disordersStem cellsProgenitor cellsRecent pre-clinical studiesHematopoietic growth factorsAttractive targetChemotherapy-associated neutropeniaStimulation of neurogenesisObserved neuroprotective effectsDifferentiationPre-clinical studies
2020
PPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders
Jamwal S, Blackburn J, Elsworth JD. PPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders. Pharmacology & Therapeutics 2020, 219: 107705. PMID: 33039420, PMCID: PMC7887032, DOI: 10.1016/j.pharmthera.2020.107705.Peer-Reviewed Original ResearchMeSH KeywordsAryldialkylphosphataseHumansNeurodegenerative DiseasesNF-E2-Related Factor 2Organelle BiogenesisPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaPPAR gammaConceptsNeurodegenerative disordersParkinson's diseaseAlzheimer's diseaseParaoxonase 2Mitochondrial biogenesisNeurodegenerative diseasesHuntington's diseasePeroxisome proliferator-activated receptorProliferator-activated receptorPotential therapeutic targetDevastating neurological disorderFunction of neuronsPeroxisome proliferator-activated receptor gamma co-activator-1 alphaPharmacological-based therapiesSymptomatic treatmentCurrent therapiesClinical trialsLigand-inducible transcription factorsTherapeutic targetNeurological disordersDiseasePPARγ modulatorsProgressive lossMitochondrial dysfunctionPromising target